Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDUCE-4: GSK3359609 plus pembrolizumab and 5-FU–platinum vs placebo plus pembrolizumab and 5-FU–platinum in first-line recurrent/metastatic HNSCC
jRCT2011200012Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing GSK3359609 + pembrolizumab + 5-FU–platinum with Placebo + pembrolizumab + 5-FU–platinum (2 arms). Primary endpoints: Overall Survival in total population, Overall Survival in PD-L1 CPS ≥1 population and 1 more. Started Jan 2021; status: completed.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2011200012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200012.